MedPath

Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology logo
🇺🇸United States
Ownership
Private
Established
2011-01-01
Employees
251
Market Cap
-
Website
https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

504

Active:43
Completed:370

Trial Phases

5 Phases

Early Phase 1:1
Phase 1:30
Phase 2:228
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (431 trials with phase data)• Click on a phase to view related trials

Phase 2
228 (52.9%)
Phase 3
155 (36.0%)
Phase 1
30 (7.0%)
Not Applicable
17 (3.9%)
Early Phase 1
1 (0.2%)

Family Communications After Genetic Testing

Not Applicable
Not yet recruiting
Conditions
Colon Adenocarcinoma
Colorectal Adenocarcinoma
Rectal Adenocarcinoma
Stage I Colon Cancer AJCC v8
Stage I Colorectal Cancer AJCC v8
Stage I Rectal Cancer AJCC v8
Stage II Colon Cancer AJCC v8
Stage II Colorectal Cancer AJCC v8
Stage II Rectal Cancer AJCC v8
Stage III Colon Cancer AJCC v8
First Posted Date
2025-08-27
Last Posted Date
2025-09-16
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
4186
Registration Number
NCT07143487

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

Not Applicable
Not yet recruiting
Conditions
Miscellaneous Neoplasm, Nos
Non-Neoplastic Condition, Nos
First Posted Date
2025-07-29
Last Posted Date
2025-07-29
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
535
Registration Number
NCT07091617

Distance-Based Exercise to Preserve Function and Prevent Disability

Not Applicable
Not yet recruiting
Conditions
Hematopoietic and Lymphatic System Neoplasm
Localized Malignant Solid Neoplasm
First Posted Date
2025-07-11
Last Posted Date
2025-07-11
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
104
Registration Number
NCT07059884

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Phase 3
Recruiting
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Interventions
Procedure: Biopsy of Bladder
Procedure: Cystoscopy
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection
Procedure: Transurethral Resection of Bladder Tumor
First Posted Date
2025-05-31
Last Posted Date
2025-09-08
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
330
Registration Number
NCT07000084
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States

and more 35 locations

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Phase 3
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Drug: Placebo
Drug: Chemotheraphy
Radiation: Radiation Therapy
Drug: Analgesic Agent
Procedure: Biospecimen Collection
Other: Survey Administration
First Posted Date
2025-05-28
Last Posted Date
2025-09-09
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
228
Registration Number
NCT06992427
Locations
🇺🇸

AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 69 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 101
  • Next

News

Dual Immunotherapy Combination Significantly Extends Survival in Advanced Cutaneous Squamous Cell Carcinoma

A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma.

Experts Debate Value of ctDNA Testing in Muscle-Invasive Bladder Cancer Management

Leading oncologists discuss the current limitations of circulating tumor DNA (ctDNA) testing in muscle-invasive bladder cancer, highlighting the need for more evidence before routine clinical implementation.

PROSPECT-Lung Trial Investigates Optimal Timing of Immunotherapy in Non-Small Cell Lung Cancer

The PROSPECT-Lung trial is evaluating whether immunotherapy is more effective when administered before or after surgery for resectable non-small cell lung cancer.

Veliparib Fails to Improve Survival in Glioblastoma Patients With MGMT Hypermethylation

A phase II/III trial evaluated the addition of veliparib to temozolomide in newly diagnosed glioblastoma patients with MGMT promoter hypermethylation.

myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS

myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.